144 related articles for article (PubMed ID: 27721341)
1. Quantification of Process Induced Disorder in Milled Samples Using Different Analytical Techniques.
Zimper U; Aaltonen J; McGoverin CM; Gordon KC; Krauel-Goellner K; Rades T
Pharmaceutics; 2010 Feb; 2(1):30-49. PubMed ID: 27721341
[TBL] [Abstract][Full Text] [Related]
2. Quantitative solid-state analysis of three solid forms of ranitidine hydrochloride in ternary mixtures using Raman spectroscopy and X-ray powder diffraction.
Chieng N; Rehder S; Saville D; Rades T; Aaltonen J
J Pharm Biomed Anal; 2009 Jan; 49(1):18-25. PubMed ID: 19081220
[TBL] [Abstract][Full Text] [Related]
3. Assessment of crystalline disorder in cryo-milled samples of indomethacin using atomic pair-wise distribution functions.
Bøtker JP; Karmwar P; Strachan CJ; Cornett C; Tian F; Zujovic Z; Rantanen J; Rades T
Int J Pharm; 2011 Sep; 417(1-2):112-9. PubMed ID: 21182911
[TBL] [Abstract][Full Text] [Related]
4. Toward understanding the evolution of griseofulvin crystal structure to a mesophase after cryogenic milling.
Feng T; Bates S; Carvajal MT
Int J Pharm; 2009 Feb; 367(1-2):16-9. PubMed ID: 19013224
[TBL] [Abstract][Full Text] [Related]
5. Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation.
Chieng N; Aaltonen J; Saville D; Rades T
Eur J Pharm Biopharm; 2009 Jan; 71(1):47-54. PubMed ID: 18644443
[TBL] [Abstract][Full Text] [Related]
6. Unravelling the relationship between degree of disorder and the dissolution behavior of milled glibenclamide.
Mah PT; Laaksonen T; Rades T; Aaltonen J; Peltonen L; Strachan CJ
Mol Pharm; 2014 Jan; 11(1):234-42. PubMed ID: 24224572
[TBL] [Abstract][Full Text] [Related]
7. Screening for differences in the amorphous state of indomethacin using multivariate visualization.
Savolainen M; Heinz A; Strachan C; Gordon KC; Yliruusi J; Rades T; Sandler N
Eur J Pharm Sci; 2007 Feb; 30(2):113-23. PubMed ID: 17169536
[TBL] [Abstract][Full Text] [Related]
8. Investigation of properties and recrystallisation behaviour of amorphous indomethacin samples prepared by different methods.
Karmwar P; Graeser K; Gordon KC; Strachan CJ; Rades T
Int J Pharm; 2011 Sep; 417(1-2):94-100. PubMed ID: 21182910
[TBL] [Abstract][Full Text] [Related]
9. The Influence of Milling on the Dissolution Performance of Simvastatin.
Zimper U; Aaltonen J; Krauel-Goellner K; Gordon KC; Strachan CJ; Rades T
Pharmaceutics; 2010 Dec; 2(4):419-431. PubMed ID: 27721365
[TBL] [Abstract][Full Text] [Related]
10. Probing Pharmaceutical Mixtures during Milling: The Potency of Low-Frequency Raman Spectroscopy in Identifying Disorder.
Walker G; Römann P; Poller B; Löbmann K; Grohganz H; Rooney JS; Huff GS; Smith GPS; Rades T; Gordon KC; Strachan CJ; Fraser-Miller SJ
Mol Pharm; 2017 Dec; 14(12):4675-4684. PubMed ID: 29091447
[TBL] [Abstract][Full Text] [Related]
11. Effect of different preparation methods on the dissolution behaviour of amorphous indomethacin.
Karmwar P; Graeser K; Gordon KC; Strachan CJ; Rades T
Eur J Pharm Biopharm; 2012 Feb; 80(2):459-64. PubMed ID: 22019529
[TBL] [Abstract][Full Text] [Related]
12. Understanding Concomitant Physical and Chemical Transformations of Simvastatin During Dry Ball Milling.
Modhave D; Saraf I; Karn A; Paudel A
AAPS PharmSciTech; 2020 May; 21(5):152. PubMed ID: 32440782
[TBL] [Abstract][Full Text] [Related]
13. Application of diffuse reflectance near-infrared spectroscopy for determination of crystallinity.
Seyer JJ; Luner PE; Kemper MS
J Pharm Sci; 2000 Oct; 89(10):1305-16. PubMed ID: 10980505
[TBL] [Abstract][Full Text] [Related]
14. Considerations on the quantitative analysis of apparent amorphicity of milled lactose by Raman spectroscopy.
Pazesh S; Lazorova L; Berggren J; Alderborn G; Gråsjö J
Int J Pharm; 2016 Sep; 511(1):488-504. PubMed ID: 27397869
[TBL] [Abstract][Full Text] [Related]
15. X-ray powder diffractometry in combination with principal component analysis--a tool for monitoring solid state changes.
Kogermann K; Veski P; Rantanen J; Naelapää K
Eur J Pharm Sci; 2011 Jul; 43(4):278-89. PubMed ID: 21575718
[TBL] [Abstract][Full Text] [Related]
16. Atomic pairwise distribution function analysis of the amorphous phase prepared by different manufacturing routes.
Boetker JP; Koradia V; Rades T; Rantanen J; Savolainen M
Pharmaceutics; 2012 Jan; 4(1):93-103. PubMed ID: 24300182
[TBL] [Abstract][Full Text] [Related]
17. [The development of co-amorphous drug systems].
Yao J; Shi NQ; Wang XL
Yao Xue Xue Bao; 2013 May; 48(5):648-54. PubMed ID: 23888685
[TBL] [Abstract][Full Text] [Related]
18. Structural evolution of indomethacin particles upon milling: time-resolved quantification and localization of disordered structure studied by IGC and DSC.
Planinsek O; Zadnik J; Kunaver M; Srcic S; Godec A
J Pharm Sci; 2010 Apr; 99(4):1968-81. PubMed ID: 20049752
[TBL] [Abstract][Full Text] [Related]
19. Quantifying low amorphous or crystalline amounts of alpha-lactose-monohydrate using X-ray powder diffraction, near-infrared spectroscopy, and differential scanning calorimetry.
Fix I; Steffens KJ
Drug Dev Ind Pharm; 2004 May; 30(5):513-23. PubMed ID: 15244087
[TBL] [Abstract][Full Text] [Related]
20. An example of how to handle amorphous fractions in API during early pharmaceutical development: SAR114137--a successful approach.
Petzoldt C; Bley O; Byard SJ; Andert D; Baumgartner B; Nagel N; Tappertzhofen C; Feth MP
Eur J Pharm Biopharm; 2014 Apr; 86(3):337-50. PubMed ID: 24075979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
